Hepion Pharmaceuticals, Pharma Two B Announce SEC Filing for Proposed Merger Transaction

MT Newswires Live09-04

Hepion Pharmaceuticals (HEPA) and Pharma Two B said Wednesday that a registration statement has been filed with the Securities and Exchange Commission for their planned merger transaction.

The companies said the registration statement, which was filed by Pharma Two B, is not yet effective and the information provided in the filing related to their proposed transaction remains subject to change.

The boards of Hepion and Pharma Two B have approved the transaction and the companies expect to close the merger in Q4. Closing conditions include the listing of Pharma Two B's common shares on Nasdaq and approvals from regulators and the companies' shareholders, according to the joint statement.

Following closing, the combined company will operate under the name Pharma Two B, the companies added.

Price: 0.77, Change: +0.02, Percent Change: +2.23

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment